Digging Deeper: How Lonza became the most important healthcare company you’ve never heard of

Lonza sits at the nexus of two of the most powerful long-term trends in global healthcare: outsourced drug production and the rise of biologic therapies. In this episode of Digging Deeper, Murdo MacLean sits down with investment manager Tom Miedema to explore the critical role this little-known Swiss group plays in advanced drug manufacturing.Together, they examine the foundations of Lonza’s competitive advantage, the resilience of its market leadership, and the potential for AI‑driven drug discovery to usher in an exciting new phase of growth.To watch the full video version of this conversation, head to our website at walterscott.com/research. Please note, there was an editorial change at 16:12 minutes on 27 May 2026, where the market share figure was corrected from “30–35%” to “15–20%”.Key takeawaysLonza is a mission-critical partner to many of the world’s most advanced pharma companies. The company is benefiting from the long-term shift towards outsourced drug production. In a world of near-shoring and trade barriers, Lonza’s global manufacturing footprint should drive market share gains. SpeakersMurdo MacLean, Client Investment ManagerTom Miedema, Investment Manager ResourcesDigging Deeper – Understanding Inditexhttps://www.walterscott.com/research/videos/digging-deeper-understanding-inditex/Digging Deeper – Understanding Keyencehttps://www.walterscott.com/research/videos/digging-deeper-understanding-keyence/Digging Deeper – Understanding Wolters Kluwer https://www.walterscott.com/research/videos/digging-deeper-understanding-wolters-kluwer/ The podcast is intended for investment professionals only and should not be construed as investment advice or a recommendation. Any stock examples discussed are given in the context of the theme being explored, and the views expressed are those of the presenters at the time of the recording.